Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1α and c-MYC

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1821-1830

  Pang, Yu Yang ^a   Wang, Ting ^a   Chen, Fang Yuan ^a   Wu, Ying Li ^a   Shao, Xia ^a   Xiao, Fei ^a   Huang, Hong Hui ^a   Zhong, Hua ^a   Zhong, Ji Hua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

2 deoxy d glucose; Glycolysis; Methylprednisolone; Synergistic effect

Indexed keywords

DEOXYGLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTIC ACID; METHYLPREDNISOLONE; MYC PROTEIN; GLUCOCORTICOID; MYC PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL HYPOXIA; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIVITY; GLUCOSE INTAKE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; UPREGULATION; CELL CULTURE; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME FACTOR; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DEOXYGLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOCORTICOIDS; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOMA, NON-HODGKIN; METHYLPREDNISOLONE; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 84932184321     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.963575     Document Type: Article

References (30)

1. Warburg E. Some historical notes on the precedence and rank of professors. Acta Derm Venereol Suppl (Stockh) 1952; 32: 376-381.
2. Hulleman E, Kazemier KM, Holleman A, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009; 113: 2014-2021.
3. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
4. Chou TC. Th eoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.
5. Chou TC, Motzer RJ, Tong Y, et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1524.
6. Caro P, Kishan A U, Norberg E, et al. M etabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell 2012; 22: 547-560.
7. Miwa H, Shikami M, Goto M, et al. L eukemia cells demonstrate a different metabolic perturbation provoked by 2-deoxyglucose. Oncol Rep 2013; 29: 2053-2057.
8. Khaitan D, Chandna S, Arya MB, et al. Differential mechanisms of radiosensitization by 2-deoxy-D-glucose in the monolayers and multicellular spheroids of a human glioma cell line. Cancer Biol Th er 2006; 5: 1142-1151.
9. Fan Y, Dickman KG, Zong WX. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem 2010; 285: 7324-7333.
10. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
11. Frolova O, Samudio I, Benito JM, et al. Regulation of HIF-1alpha signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Th er 2012; 13: 858-870.
12. Wang Q, Liang B, Shirwany NA, et al. 2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen species-mediated activation of the AMP- Activated protein kinase. PLoS One 2011; 6: e17234.
13. Oudard S, Carpentier A, Banu E, et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2003; 63: 81-86.
14. Raez LE, Lopes G, Lilenbaum R. Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 4244-4245.
15. DiPaola RS, Lattime EC. Bacillus Calmette-Guerin mechanism of action: The role of immunity, apoptosis, necrosis and autophagy. J Urol 2007; 178: 1840-1841.
16. Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005; 181: 507-514.
17. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000; 275: 21797-21800.
18. Gordan JD, Th ompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007; 12: 108-113.
19. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
20. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007; 53: 233-256.
21. Greijer A E, v an der Groep P, Kemming D, et al. U p-regulation of gene expression by hypoxia is mediated predominantly by hypoxiainducible factor 1 (HIF-1). J Pathol 2005; 206: 291-304.
22. Chen C, Pore N, Behrooz A, et al. R egulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001; 276: 9519-9525.
23. Evens AM, Schumacker PT, Helenowski IB, et al. Hypoxia inducible factor- Alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol 2008; 141: 676-680.
24. Giatromanolaki A, Koukourakis MI, Pezzella F, et al. Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin ' s lymphomas and correlate with hypoxia inducible factor activation. Hematol Oncol 2008; 26: 219-224.
25. Passam F H, A lexandrakis M G, Kafousi M, et al. H istological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma. Pathol Res Pract 2009; 205: 11-20.
26. Zhong D, Liu X, Schafer-Hales K, et al. 2-Deoxyglucose induces Akt phosphorylation via a mechanism independent of LKB1/AMPactivated protein kinase signaling activation or glycolysis inhibition. Mol Cancer Th er 2008; 7: 809-817.
27. Zhong D, Xiong L, Liu T, et al. The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem 2009; 284: 23225-23233.
28. Xi H, Kurtoglu M, Liu H, et al. 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol 2011; 67: 899-910.
29. Xi H, Barredo JC, Merchan JR, et al. Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKbeta leading to autophagy. Biochem Pharmacol 2013; 85: 1463-1477.
30. Deng L, Lei Y, Liu R, et al. Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis 2013; 4: e614.